Large streamlined trials in cardiovascular disease

Calvo, G. et al. (2014) Large streamlined trials in cardiovascular disease. European Heart Journal, 35(9), pp. 544-548. (doi:10.1093/eurheartj/eht535)

Full text not currently available from Enlighten.


In the search for new and better therapies, reliable evidence of efficacy and safety—usually provided from large-scale randomized trials—is essential to support licensing, inform guidelines, and change clinical practice. However, the size, duration, complexity, and costs of conducting contemporary clinical trials have risen steadily. This coupled with an apparently diminishing likelihood of a positive trial has raised concerns about return on investment to the point of restricting drug development in cardiovascular diseases (CVD).1

More efficient ways to conduct randomized trials need to be developed with engagement by the various stakeholders.

Item Type:Articles
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Calvo, G., McMurray, J.J.V., Granger, C.B., Alonso-Garcia, A., Armstrong, P., Flather, M., Gomez-Outes, A., Pocock, S., Stockbridge, N., Svensson, A., and Van de Werf, F.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:European Heart Journal
Publisher:Oxford University Press
ISSN (Online):1522-9645

University Staff: Request a correction | Enlighten Editors: Update this record